Aurinia制药 AUPH 深 沪
已收盘 12-19 16:00:00 美东时间
16.18
+0.270
+1.70%
华盛通- 最 高16.40
- 今 开16.01
- 成交量 135.88万股
- 最 低 15.935
- 昨 收 15.91
- 总市值 21.36亿
- 52周最高 16.48
- 市盈率 静 411.70
- 换手率 1.03%
- 52周最低 6.55
- 委 比 5.15%
- 总股本 1.32亿
- 历史最高 33.972
- 量 比 1.34
- 振 幅 2.92%
- 历史最低 1.41
- 每 手 1
- 风险率 2.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform, Raises Price Target to $16
Leerink Partners analyst Joseph Schwartz downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Market Perform and raises the price target from $15 to $16.
12-03 21:33
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Aurinia downgraded at RBC on risk-reward setup
Aurinia Pharmaceuticals (AUPH) traded lower on Wednesday as RBC Capital Markets downgraded the stock, citing an uneven risk-reward profile after the biotech added over ~8% in the previous session in r...
11-06 00:27
RBC Capital Downgrades Aurinia Pharmaceuticals to Sector Perform, Raises Price Target to $15
RBC Capital analyst Douglas Miehm downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Sector Perform and raises the price target from $9 to $15.
11-05 20:36
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Aurinia Pharmaceuticals Raises FY2025 Sales Guidance from $260.000M-$270.000M to $275.000M-$280.000M vs $270.478M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) raises FY2025 sales outlook from $260.000 million-$270.000 million to $275.000 million-$280.000 million vs $270.478 million estimate.
11-04 19:01
Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.16 Estimate, Sales $73.468M Beat $67.418M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.16 by 43.75 percent. This is a 130 percent increase over earnings of $0.10 per share
11-04 19:00
